{
  "docId": "019de077-03c2-7682-9c49-749c55840a7d",
  "docSlug": "7d4a71c8904800c2c7c70f8e07dfcf66",
  "documentTitle": "Exscientia | Results Presentation Deck | 22 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 22,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a human anatomy diagram to map specific cancer types to their physiological locations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-03c2-7682-9c49-749c55840a7d/14",
  "deckHref": "/decks/019de077-03c2-7682-9c49-749c55840a7d",
  "deckJsonHref": "/decks/019de077-03c2-7682-9c49-749c55840a7d.json",
  "deckAnchorHref": "/decks/019de077-03c2-7682-9c49-749c55840a7d#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Covers all indications included in Ph1/2 ELUCIDATE trial; Patient counts for each subtype based on EvaluatePharma Epidemiology 2022 and primary inclusion criteria for ELUCIDATE Ph 1/2 trial. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; *Excludes currently actionable driver mutations such as ALK, EGFR, BRAF, ROS1, RET and MET",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fde897d4-ce39-4108-a918-01370a92f380",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.9,
        "w": 0.235,
        "x": 0.229,
        "y": 0.189
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ae4ee06-f923-46d2-82cd-50f7c3feec5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "list",
      "text": "5K Head & Neck Cancer; 29K Non-small Cell Lung Cancer; 6K Ovarian Cancer; 12K Breast Cancer; 8K Pancreatic Cancer; 15K Colorectal Cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "366ff52d-c131-4fa8-80aa-76758465db04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.68,
        "y": 0.45
      },
      "kind": "metric",
      "text": "~75K U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "927ece43-816b-47af-ad81-ea073feae86b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for patient sub-groups included in ELUCIDATE trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0906ac4f-c072-4177-9ce1-69c625758e0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ad1004a-ca90-4f75-823d-aa248aa59b7f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "bd5938c7-35db-4116-86d5-d5b5b7e92b80",
      "evidence": "list/bullet: 5K Head & Neck Cancer; 29K Non-small Cell Lung Cancer; 6K Ovarian Cancer; 12K Breast Cancer; 8K Pancreatic Cancer; 15K Colorectal Cancer",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "fe6dac0a-23d3-4c88-b821-f1fb4c12ee3c",
      "evidence": "Breakdown of total addressable patient population by specific sub-indications.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 13,
      "beatId": "ac22c057-1c2d-4a7e-9615-3a68519957b2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck showcases pipeline updates and proposed solutions",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 13,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "59bbe9a5-4dee-402a-a171-3cbe1ef4dc26",
      "evidence": "The deck presents a logic chain with pipeline updates and proposed solutions",
      "position": 1,
      "objective": "How does Exscientia's pipeline support its growth strategy?",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.6,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}